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Abstract
Transcriptome data can facilitate the interpretation of the effects of rare genetic variants. Here, we
introduce ANalysis of Expression VAriation (ANEVA) to quantify genetic variation in gene
dosage from allelic expression (AE) data in a population. Application of ANEVA to the GenotypeTissues Expression (GTEx) data showed that this variance estimate is robust and correlated with

Author Manuscript

*This manuscript has been accepted for publication in Science. This version has not undergone final editing. Please refer to the
complete version of record at http://www.sciencemag.org/. The manuscript may not be reproduced or used in any manner that does not
fall within the fair use provisions of the Copyright Act without the prior, written permission of AAAS.
❖

Corresponding authors.
Authors contributions: P.M. and T.L. designed the study. P.M. developed all statistical models, P.M., S.E.C., B.C., and J.E. analyzed
the data, and P.M., C.S., and PH. developed software tools. S.D., Z.J., Pa.M., A.R.F., H.E.W., H.K.I., C.G.B., and D.G.M. provided
data and materials. P.M. and T.L. wrote the paper with input from all the authors.

Competing interests: D.G.M. is a founder with equity, and T.L. is an advisor in Goldfinch Bio. S.E.C. is a co-founder, chief
technology officer, and stock owner in Variant Bio. T.L. is an advisor with equity in Variant Bio. H.K.I. has received honoraria from
GSK and AbbVie. The other authors have no competing interests.
Data and materials availability: Software packages for the presented methods are available online: BLN distribution functions (31),
ANEVA (32), ANEVA-DOT (24). Outlier summary statistics for all GTEx tissues are available in (33). The GTEx v7 data is available
in dbGap (phs000424.v7.p2), and the MDM cohort data is available in dbGap phs000655. Gene level AE data and ANEVA-DOT
results in MDM cohort is given in supplementary Data S1.

Mohammadi et al.

Page 2

Author Manuscript

selective constraint in a gene. Using these variance estimates in a Dosage Outlier Test (ANEVADOT) applied to AE data from 70 Mendelian muscular disease patients showed accuracy in
detecting genes with pathogenic variants in previously resolved cases, and lead to one confirmed
and several potential new diagnoses. Using our reference estimates from GTEx data, ANEVADOT can be incorporated in rare disease diagnostic pipelines to utilize RNA-seq data more
effectively.

One Sentence Summary:
New statistical framework for modeling allelic expression characterizes genetic regulatory
variation in populations and informs diagnosis in rare disease patients

Background
Author Manuscript

Large reference databases of human exomes and genomes have enabled the characterization
of genomic variation in human populations (1–3). These data have been used to summarize
genic intolerance to damaging variants, where depletion of gene disrupting variants (e.g.
stop gain variants) indicates deleterious fitness consequences (1, 4, 5). Such analyses are
essential for prioritizing rare and de novo coding variants that can underlie Mendelian
disease and provide a genetic diagnosis for 25–50% of the patients (6, 7). However, despite
advances in DNA sequencing, the search for rare disease-causing variants outside the coding
sequence has been hindered by the difficulty of interpreting rare regulatory variants and
identifying their target genes.

Author Manuscript

Integration of genome and transcriptome sequencing data has provided improved diagnosis
via better detection of rare variants with functional effects (6, 8–10). However, the often
laborious analysis is further complicated by the transcriptome being affected by the
environment, disease state, and technical variation. This has made it challenging to quantify
when an effect is genetic and beyond the normal population range. Thus, most analyses have
been limited to only a small fraction of variants that induce clear alterations in the
transcriptome, such as total loss of expression and splice defects.
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One promising data type is the allelic expression (AE) which measures the relative
expression of the paternal and maternal haplotype of a gene in an individual. Departure from
equal AE, allelic imbalance, is largely unaffected by environmental and technical factors
with a reported heritability of 85% (11), and therefore, has a unique sensitivity to capture
cis-acting genetic effects including those induced by rare variants (6, 12–14) (15). However,
a quantitative framework for interpreting this unique data type to identify rare pathogenic
variants has been lacking.
Here, we quantify the effects of genetic regulatory variation in populations using a
mechanistic model of cis-regulatory variation. Specifically, for each gene we estimate VG,
the expected variance in the dosage that is due to inter-individual genetic differences within
a population. Next, we use VG as a reference to identify genes affected by potentially
pathogenic regulatory variants in patients.

Science. Author manuscript; available in PMC 2020 April 18.
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Results
A generative model for population allelic expression data and the ANEVA method
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Cis-regulatory variant effect sizes can be quantified with allelic fold change (aFC; (16)).
AFC has an analytical link to gene dosage, which would allow calculation of VG if all
regulatory variants were known (Eq. 1–7). In practice, we can use AE data to estimate the
overall distribution of regulatory effects on a gene without having to identify these variants
explicitly. Across individuals, AE data represents a series of comparisons between net
expression effects of all variants on two random haplotypes at a time. A major complication
for applications of AE data is that within a population, it has diverse patterns depending on
the properties of regulatory variants present and the SNP used to measure the allelic
expression (aeSNP; Fig. 1A–D; (14, 15)). We derive a generative model for population AE
data under a realistic scenario where a gene is regulated by several regulatory variants of
which only some are identifiable. Under this assumption, population AE data is described by
a constrained mixture of Binomial-Logit-Normal (BLN) probability distribution functions
(Eq. 8–19). We fit this model to population AE data (Eq. 20–28, Fig. 1E–H) and use the
maximum likelihood parameters to estimate VG indirectly (Eq. 29–30). We refer to this
method as ANalysis of Expression Variation (ANEVA). Simulations show that the inferred
VG is accurate (R2 =0.92, Fig. S1). Thus, ANEVA allows one to derive biologically
interpretable estimates of genetic variation in gene expression within a population from AE
read count data.
ANEVA estimates from AE data are consistent with eQTL data and heritability of gene
expression

Author Manuscript

We applied ANEVA to 10,361 RNA-seq samples from 48 tissues and 620 individuals with
whole genome sequencing (WGS) data from the GTEx v7 data (17, 18). Overall, we
estimated VG at a median of 43,219 autosomal aeSNPs per tissue. Gene-level VG was
derived as a weighted harmonic mean of SNP-level estimates for a median of 4,962 genes
per tissue, and a total of 14,084 genes (Fig. 2A–B, Table S1). First, we ensured that our AEderived estimates of VG were consistent with what is expected from eQTL data (median
corr. SDG = 0.73; Figs. 2C, S2, Table S2). Next, we benchmarked ANEVA estimates against
gene expression cis-heritability (h2). For GTEx whole blood, we calculated the ratio of AE
and eQTL-derived VG to the total variance of gene expression (VT). These ANEVA-based
h2 estimates were consistent and comparable with those from standard methods and larger
data sets, confirming that VG measures the genetic variation in gene expression (Figs. 2D,
S3). Since AE-based ANEVA VG estimates are better applicable to AE-based outlier
detection, we used these estimates for all subsequent analyses (Fig. S14, (19)).

Author Manuscript

Genetically driven variation in gene expression across tissues, populations and gene sets
Next, we analyzed how VG varies between tissues and populations. The estimates were well
correlated between tissues (median corr. SDG =0.57; Fig. 3A). For a given gene, VG tends to
be smaller in tissues where the gene is more highly expressed (Wilcoxon signed rank test
P<10–300; Fig. 3B). Since this was not an artifact of differences in read depth (Fig. S4), it
suggests that there is an increased dosage sensitivity and a higher selective constraint in
tissues where the gene has a more pronounced functional role (see Fig. S5 for an example).
Science. Author manuscript; available in PMC 2020 April 18.
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To analyze population differences in VG, we used ANEVA on AE data from three European
and one African subpopulation from GEUVADIS data (22). We found a high correlation
between estimates from all subpopulations (corr. range: [0.75, 0.83]; Fig. S6). This suggests
that the total amount of genetic dosage variation is not highly variable between populations,
and approaches that aggregate genetic effects at the gene level may have better applicability
across populations than analyses of individual variants.
To characterize differences in the amount of genetic regulatory variation between genes, we
correlated VG to statistics of gene regulation and constraint. For each gene, we calculated a
weighted harmonic mean of VG across tissues (VG; Table S1). Gene enhancer size had a

Author Manuscript

minimal correlation to VG (Fig. 3C; (23)), suggesting that the size of the mutational target, a
proxy for the background mutation rate plays a minor role. Genes with high purifying
selection for coding gene disrupting variants, or noncoding variants in the promoter or UTR
regions, were depleted of genetic regulatory variation (Fig. 3C), as previously observed by
eQTL analysis (1). Rare disease genes had lower VG, while loss of function tolerant genes

had higher VG (Fig. 3D), showing that dosage sensitivity is captured by both exome and
regulatory variation analysis. Genes identified by genome wide association studies (GWAS)
showed little deviation from the background, but schizophrenia genes having the lowest VG,
and blood metabolite genes the highest suggests a link to genetic architecture of these traits.
Altogether, the amount of genetic regulation variation measured as VG can complement
previous coding and regulatory variation analyses of selective constraint on genes and traits.
Genetically driven variation in gene expression and dosage outlier testing from AE data

Author Manuscript

In addition to these biological insights, VG has a direct practical application in identifying
population outliers that may be pathogenic. To this end, we developed ANEVA Dosage
Outlier Test (ANEVA-DOT) to identify genes likely affected by a heterozygous genetic
variant with an unusually strong effect on gene dosage. Using VG for each gene, ANEVADOT tests against the null hypothesis that the observed allelic imbalance in an individual is
consistent with dosage variation in the general population (Fig. 4A) while accounting for a
number of additional technical and biological sources of variation (Eq. 31–42). We used
extensive simulations to ensure that the test is well calibrated (Fig. S7). ANEVA-DOT is
implemented in R, and it runs in a few seconds per sample (24).

Author Manuscript

We first tested ANEVA-DOT in the general population of 466 skeletal muscle samples from
GTEx. Each sample had a median of 3,390 genes tested and 10 genes identified as outliers at
5% FDR (hereafter ANEVA-DOT genes; 90% range: [3, 22]). An average of 56% of the
genes previously implicated in neuromuscular disorders (6, 25), and up to 46% of the highly
expressed genes were testable per individual (Fig. S8). As a quality filter, 113 out of 5848
tested genes that appeared as outliers in >1% of the individuals were excluded from further
analysis (Fig. S8D–F, Table S4). After this step, a median of 4.5 ANEVA-DOT genes were
retained per individual (90% range: [1, 14]; Fig. 4B). ANEVA-DOT genes were highly
enriched for rare heterozygous variants in a 10kb window upstream of the TSS and in the
gene body (Fig. 4B). This enrichment was particularly pronounced for rare putative gene
disrupting variants that are expected to have a strong effect on gene expression levels via
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nonsense-mediated decay (Fig. 4B–C). This confirms that ANEVA-DOT captures rare
genetic effects on gene dosage.
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Next, we evaluated how sensitive ANEVA-DOT is to differences in the reference population
where VG is calculated. First, using the GEUVADIS data (22), we looked for ANEVA-DOT
genes in 86 European (GBR) individuals using VG estimates derived from two European
(FIN and TSI), and one African (YRI) populations. The three reference populations
performed similarly with an average of 74% (69%–78%) of ANEVA-DOT genes identified
using one confirmed by another (Fig. S9), suggesting that the lack of full concordance is
likely driven by noise and threshold effects. However, larger sample sizes will be needed for
a comprehensive evaluation of the population effects._Next, we checked if ANEVA-DOT
genes in GTEx skeletal muscle could be identified by analyzing other accessible tissues of
these individuals. The detection rate varied from 23.3% in fibroblast to 12.3% in whole
blood, which indicates that ANEVA-DOT can capture some outlier effects also from proxy
tissues (Fig. S10).
ANEVA-DOT accurately identifies disease genes in AE data from rare disease patients

Author Manuscript

To test ANEVA-DOT’s performance in the diagnosis of rare disease patients, we applied it
to AE data from 70 rare Mendelian muscle dystrophy and myopathy (MDM) patients using
VG reference from GTEx skeletal muscle (Figs. S11–S17, Table S5). Out of the 65 patients
with high quality data, 32 have a previous diagnosis, of which 21 are expected to lead to
allelic imbalance (6). These cases were used as positive controls to benchmark ANEVADOT against previous tests of allelic imbalance: binomial and beta-binomial tests, binomial
test with an allelic imbalance threshold, and a naive population-aware test of excess allelic
imbalance against GTEx data via z-test (Fig. 4D–H, Fig. S12). ANEVA-DOT identified a
median of 11 outlier genes per individual (out of a median of 2190 tested), substantially less
than other tests, (Fig. 4H). This small number of outliers always included the previously
diagnosed gene when there was a detectable allelic imbalance present (76%; Figs. S11–
S12), typically (69%) among the top-five most significant genes (Table S5). ANEVA-DOT’s
high recall and precision outperformed all the other tests by a substantial margin (Figs. 4I,
S12–S14, (19)).

Author Manuscript

In the 33 patients without a genetic diagnosis from previous WES and/or WGS or RNA-seq
analysis (6), we found a median of nine ANEVA-DOT genes per sample (in total 349 genes),
which included at least one neuromuscular disease gene (6, 25) in 12 patients (in total 17
genes; Figs. S15–S16). One of these potential new diagnoses from ANEVA-DOT was
confirmed: Patient N10, with limb-girdle muscular dystrophy-like phenotype, had 13
ANEVA-DOT genes, with the one known Mendelian muscle disease gene, DES being the
most significant. Further RNA-sequencing and RT-PCR analysis identified a pseudo-exon
insertion caused by a variant creating an intronic splice site. This had been missed by the
prior gene panel, WES, WGS and RNA-seq analysis due to challenging in silico
interpretation of intronic variants and the relatively low number of RNA-seq reads. The
variant is in trans with a pathogenic missense variant that had not been identified as a
diagnosis due to the lack of a second variant (Fig. S18). Additionally, ANEVADOT
identified strong candidates in six cases and possible candidates in 11 others (19). By design,
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ANEVADOT does not rely on identifying which variant underlies the dosage outlier effect,
but genetic analysis can be applied after prioritizing genes by ANEVADOT. This is currently
mostly limited to gene or splice disrupting variants due to their easier annotation compared
to rare regulatory variant candidates that may also exist. Overall, we expect up to 10.5 of the
17 known MDM, and 18.8 of all 349 identified ANEVADOT genes in the 33 undiagnosed
patients to be true disrupted causative genes (19).

Discussion

Author Manuscript

In this study, we introduce a method, ANalysis of Expression VAriation (ANEVA), and its
extension ANEVA Dosage Outlier Test (ANEVA-DOT) to quantify genetic variation in gene
dosage in the general population, and to identify genes where a patient appears to carry a
heterozygous variant with an unusually strong effect on gene expression. This enables
individual transcriptome comparison to previously generated reference data without the
caveats of technical and reverse causation noise in total gene expression analysis.
The ANEVA framework uses biologically interpretable units of gene dosage, allowing
interpretation of regulatory and coding gene disrupting variants on the same scale.
Furthermore, the statistical methods introduced here for modeling allelic expression data are
applicable to other uses of this data type.

Author Manuscript

ANEVA-DOT is a fast and powerful approach for finding genes with likely disease effects,
with the small numbers of outliers making further manual curation feasible in a clinical
setting without compromising on sensitivity. The use of VG estimates from GTEx as a
shared reference for ANEVA-DOT analysis of patients is analogous to use of coding
constraint metrics for prioritization of pathogenic coding variants. ANEVA-DOT outlier
genes can be further prioritized by candidate gene lists and by tools that are currently used in
exome sequencing follow-up (1, 2, 5, 26, 27). Since ANEVA-DOT captures transcriptome
outcomes of genetic effects without having to identify rare regulatory variants themselves,
this method is particularly advantageous for rare genetic effects from poorly defined
regulatory elements, but it will also detect, for example, variants triggering transcript decay.
However, identifying the specific variants underlying ANEVA-DOT outliers is still
challenging despite existing variant prioritization approaches, especially for noncoding
regions (28–30).

Author Manuscript

Despite these advantages, our methods have several limitations. The main caveat is that AE
data is sparse, and VG estimates may be lacking or noisy for genes with few common coding
variants due to small size or high coding constraint, or low expression levels. These issues
will, however, improve with increasingly large RNA-seq data sets. ANEVA-DOT is only
applicable to about half of expressed genes per individual that have an aeSNP. Finally, allelic
imbalance is not informative of recessive effects without family analysis. Thus, similarly to
other genetic diagnosis tools, ANEVA-DOT should be used in conjunction with other
methods to capture different types of rare variants underlying disease. We envision that in
clinical genetics, when practically feasible, transcriptome data will become a powerful
additional layer of data for interpreting the genome and its disease-contributing variants.
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Figure 1: Cis-regulatory variation, allelic expression, and ANEVA.
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A–D) Examples of allelic expression across individuals (dots) for four genes with a single
aeSNP each. In (A) similar haplotype expression levels for the gene indicate little cisregulatory variation. In (B–D) there is relatively more variation. In (C–D) there are distinct
clusters driven by different haplotype combinations of a common, strong regulatory variant
and the aeSNP, with strong linkage disequilibrium in (D). These examples illustrate the
challenge of consistently modeling the underlying regulatory variants. E) Schematic
representation of ANEVA, which uses a generative model of population AE data and a
mechanistic model of cis-regulatory variation to estimates the magnitude of genetic variation
in expression for each gene. F–H) A generative model of population AE data, represented
mechanistically (F), in population AE data (G), and as Bayesian plate diagram (H; Eq. 20–
22). AE data is modeled with one distinctly strong regulatory bi-allelic variant. If present,
this variant is specified by its effect size, SH,L, and its LD with the aeSNP. Residual cisregulatory variation is modeled as an infinite-allelic regulatory variant summarized by
variance term σ2r . Allelic expressions eR and eA are measured at a heterozygous aeSNP with
reference (R) and alternative (A) alleles, and s*R,A is the aeSNP reference allele alignment
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bias. Haplotypes h1 and h2, basal expression level eB, and N cis-regulatory variant sites v1…
vN, are components of our complete formal model of cis-regulatory variation.
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Figure 2: Estimates of genetic regulatory variation in GTEx

A) Number of genes with VG estimates across 1 to 49 GTEX tissues; B–C) Distribution of
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SDG, VG, for 7556 genes in GTEx subcutaneous adipose (B), and its comparison to eQTL
data (C; corr.=0.71). The red line is Deming regression fit (Fig. S2). SDG is capped at 0.5 for
visualization. D) Benchmarking of ANEVA by gene expression heritability (h2) estimates.
GTEx h2 was calculated by the linear mixed model based BSLMM, PrediXcan R2, and
ANEVA (19). These were compared to two larger cohorts: BLSMM h2 from the DGN
cohort (n=922; (20)), and local identity-by-descent (IBD) based h2 from the IFB cohort
(n=722; (21)).
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Figure 3: Biological sources of regulatory variation between genes.
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A) Correlation of genetic regulatory variation across GTEx tissues (see Table S1 for tissue
names). B) Rank correlation between median expression in a tissue and VG for 9,158 genes
with VG estimates in at least five tissues. The distribution is shifted (median rank corr.
−0.20). Significant genes are shown in red (5% FDR). C) Rank correlation of VG with
enhancer size, coding constraint (RVIS, pLI), and noncoding constraint (ncRVIS) and

conservation (ncGERP) in UTRs and promoters. D) VG for different gene sets (DD:
Developmental disorder, CHD: Congenital heart disease, MDM: Congenital Muscular
dystrophies and myopathies; Table S3), with nominal p-values from ranksum test compared
to the background of all genes (p-value ≤ 0.01 highlighted), with the number of genes in
parentheses. Boxes span the middle 50% values, and the whiskers span ±1.5 IQR from first
and the third quartile.
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Figure 4: Regulatory outliers detected with the ANEVA Dosage Outlier Test.

Author Manuscript

A) Illustration of the ANEVA-DOT method. For each gene, the null distribution of allelic
imbalance is estimated using the VG and the model of cis-regulatory genetic effect. Allelic
counts in a test individual are compared to this null, accounting for sampling noise,
sequencing noise, reference bias, and the variant haplotype. B–C) Enrichment of all rare
variants in ANEVA-DOT genes as a function of allele frequency (B) and for putative genedisrupting variants (MAF<1%; C). D–H) An example of AE data for all genes from one
previously diagnosed muscle dystrophy patient (N13). The disease gene is shown in blue.
Outlier genes identified by different tests (5% FDR) are marked in red: binomial (n=387; D),
binomial with a 15% allelic imbalance threshold (Bin-Thr, n=246; E), beta-binomial (BetaBin, n=83; F), excess allelic imbalance against GTEx data via z-test (AI z-test, n=94; G),
and ANEVA-DOT (n=15; H). Genes marked in grey are excluded from each test. I) Fraction
of true causal genes identified in previously diagnosed patients (recall) and its 95% bootstrap
confidence intervals versus the number of outliers reported. Empirical recall (left) is
calculated using all cases where imbalanced AE would be expected (n=21), while idealized
recall (right) excludes five cases in which detecting the gene from AE data is impossible
(e.g. when the causal gene is not expressed; Fig. S12).
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